Department of Dermatology, College of Medicine, Chosun University, 61453 Gwangju, Korea.
Acta Derm Venereol. 2020 Jun 9;100(12):adv00165. doi: 10.2340/00015555-3515.
Atopic dermatitis (AD) is a chronic, inflammatory cutaneous disease that is characterized by complex immune dysregulation and skin barrier dysfunction with a wide variety of clinical phenotypes. Until recently, conventional therapeutic modalities for AD remained rather non-specific despite AD's complex etiology. Failing to take into account the underlying inflammatory pathways led to treatments with inadequate efficacy or unacceptable long-term toxicities. We are currently in the midst of a therapeutic renaissance in AD. Recent progress in molecular medicine provides us a better understanding of the AD pathogenesis, suggesting a dominant helper T cell (Th) 2/Th22 response with a varying degree of Th1/Th17 overexpression. Targeted therapeutic agents including biologics and small molecule inhibitors in development hold promises for more effective and safer therapeutic approaches for AD. A better understanding of individual differences amongst AD patients will allow for a more tailored approach in the future. This review aims to cover the most promising emerging therapies in the field of atopic dermatitis utilizing recently published manuscripts and up-to-date conference abstracts and presentations.
特应性皮炎（AD）是一种慢性炎症性皮肤病，其特征是免疫失调和皮肤屏障功能障碍复杂，具有多种临床表型。尽管 AD 的病因复杂，但直到最近，AD 的常规治疗方法仍然相当非特异性。未能考虑到潜在的炎症途径导致治疗效果不足或不可接受的长期毒性。我们正处于 AD 的治疗复兴之中。分子医学的最新进展使我们更好地了解 AD 的发病机制，提示存在主导辅助性 T 细胞（Th）2/Th22 反应，伴有不同程度的 Th1/Th17 过度表达。正在开发的靶向治疗药物包括生物制剂和小分子抑制剂，为 AD 提供了更有效和更安全的治疗方法的希望。更好地了解 AD 患者之间的个体差异将有助于未来采用更具针对性的方法。本综述旨在利用最近发表的文献和最新的会议摘要和演讲，涵盖特应性皮炎领域最有前途的新兴疗法。
